On Thursday, for instance, two companies made their rebut in NASDAQ, Kythera Biopharmaceuticals (NASDAQ:KYTH) that develops a drug for face fat reduction, and Intercept Pharmaceuticals (NASDAQ:ICPT) that focuses on the treatment of chronic liver diseases Both stocks traded above their IPO prices in early afternoon trade.
FORBES: IPOs, FDA Approvals, and M&A Revive the Biotechnology Industry